Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 90 Breast Neoplasms 87 Melanoma 86 Multiple Myeloma 69 Carcinoma, Non-Small-Cell Lung 63 Leukemia, Myeloid, Acute 62 Lymphoma 59 Brain Neoplasms 57 Glioblastoma 55 Ovarian Neoplasms 51 Neoplasms 51 Carcinoma, Renal Cell 49 Lymphoma, Non-Hodgkin 47 Fallopian Tube Neoplasms 47 Leukemia, Lymphocytic, Chronic, B-Cell 45 Sarcoma 44 Gliosarcoma 43 Neoplasm Metastasis 39 Lung Neoplasms 36 Carcinoma, Hepatocellular 35 Precursor Cell Lymphoblastic Leukemia-Lymphoma 34 Pancreatic Neoplasms 33 Glioma 33 Lymphoma, Large B-Cell, Diffuse 32 Uterine Cervical Neoplasms 31 Hematologic Neoplasms 31 Colonic Neoplasms 31 Small Cell Lung Carcinoma 29 Myelodysplastic Syndromes 28 Rhabdomyosarcoma 27

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Has results × Lupus Nephritis × Clear all

NCT00447265 2013-02-12

Etanercept for the Treatment of Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Terminated

1 enrolled 15 charts

Lupus Nephritis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡